Pharmaceutical giant Merck & Co. is eyeing a purchase of cancer-focused biotech Seagen Inc., according to people familiar with the matter.
Talks have been under way for a while and a deal isn’t imminent, the people said, cautioning that pulling one off could be tricky given the heightened risk of a regulatory challenge. It is possible the companies could end up striking a marketing agreement instead, some of the people said.
